Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Ankrin Therapeutics ApS
APS
Bankrupt
Advertising protection
CVR 39788705
Nordre Fasanvej 215, 2000
Frederiksberg
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2018 · 7 years old
4 employees
Monitor
Share
Denmark
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Ankrin Therapeutics ApS
Overview
Financials
People & ownership
Related companies
Loading company…
People & ownership
Management
Actively employed in the business
Name
Role
Member since
Former (2)
TM
Thomas Michael Frimurer
Management
Management
2018 – 2025
AG
Anja Groth
Management
Management
2018 – 2025
Board of directors
Non-executive oversight
Name
Role
Member since
Former (2)
US
Ulrik Svane Sørensen
Chairman
Chairman
2020 – 2021
JA
Jimmy Arnold Van heusden
Chairman
Chairman
2021 – 2025
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Frimurer Holdings ApS
Company
33.33–49.99%
33.33–49.99%
2019
Svasø Holding ApS
Company
25–33.32%
25–33.32%
2019
Groth Holdings ApS
Company
33.33–49.99%
33.33–49.99%
2019
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
More on Ankrin Therapeutics ApS
Overview →
Headline figures, risk assessment and company summary
Financials & key figures →
Revenue, EBITDA, balance sheet and 5-year trend
Related companies →
Corporate hierarchy, parent and subsidiary network
